首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal DEPDC1 Antibody

  • 中文名: DEPDC1抗体
  • 别    名: DEP.8; SDP35; DEPDC1A; DEPDC1-V2
货号: IPDX08235
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/1000-1/2000 Human,Mouse,Rat

产品详情

AliasesDEP.8; SDP35; DEPDC1A; DEPDC1-V2
WB Predicted band size93 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenFusion protein of human DEPDC1
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于DEPDC1抗体的3篇参考文献概览:

1. **文献名称**: *DEPDC1 as a Biomarker for Aggressiveness in Hepatocellular Carcinoma*

**作者**: Yamamoto Y, et al.

**摘要**: 研究通过免疫组化(IHC)和Western blot分析肝细胞癌(HCC)组织中DEPDC1蛋白的表达,发现其高表达与肿瘤分化程度低、转移风险增加及患者生存率降低显著相关,提示DEPDC1可能作为HCC预后的生物标志物。

2. **文献名称**: *DEPDC1 Promotes Bladder Cancer Cell Proliferation via Akt/mTOR Signaling*

**作者**: Li H, et al.

**摘要**: 该研究利用DEPDC1抗体进行流式细胞术和免疫荧光实验,发现DEPDC1在膀胱癌细胞中过表达,并通过激活Akt/mTOR通路促进肿瘤增殖,敲低DEPDC1可抑制体内外肿瘤生长。

3. **文献名称**: *DEPDC1 as a Therapeutic Target in Triple-Negative Breast Cancer*

**作者**: Chen R, et al.

**摘要**: 通过Western blot和IHC检测三阴性乳腺癌(TNBC)样本,发现DEPDC1在TNBC中高表达且与化疗耐药相关。抗体阻断实验表明靶向DEPDC1可增强化疗敏感性,提示其作为联合治疗靶点的潜力。

以上研究均使用DEPDC1抗体验证蛋白表达,并探讨其在癌症进展中的作用机制及临床意义。

背景信息

DEPDC1 (DEP Domain-Containing Protein 1) is a protein-coding gene implicated in cell cycle regulation and carcinogenesis. It belongs to the GATOR1 complex, which negatively regulates the mTORC1 signaling pathway, a critical regulator of cell growth and metabolism. Dysregulation of DEPDC1 has been linked to tumor progression, with overexpression observed in various cancers, including bladder, liver, and breast cancers, where it correlates with poor prognosis. Antibodies targeting DEPDC1 are essential tools for investigating its expression, localization, and functional roles in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in clinical samples or experimental models. Research suggests DEPDC1 may serve as a potential biomarker for cancer diagnosis or a therapeutic target, driving interest in developing specific and validated antibodies. Commercial DEPDC1 antibodies are typically raised against epitopes within its conserved N-terminal or C-terminal regions, with validation including knockout cell line controls. However, variability in antibody performance across applications requires careful optimization. Ongoing studies focus on elucidating DEPDC1’s interplay with mTOR-related pathways and its impact on cancer cell proliferation, apoptosis, and drug resistance.

客户数据及评论

折叠内容

大包装询价

×